Article info
Therapeutics/Prevention
Randomised controlled trial
Initiating antiretroviral therapy in HIV-infected patients with >500 CD4 cells/µL provides more benefit than delaying treatment
- Correspondence to : Professor George W Rutherford, Department of Global Health Sciences, University of California, San Francisco, Mission Hall, 550 16th Street, P.O. Box 1224, San Francisco, CA 94143-1224, USA; george.rutherford{at}ucsf.edu
Citation
Initiating antiretroviral therapy in HIV-infected patients with >500 CD4 cells/µL provides more benefit than delaying treatment
Publication history
- First published December 11, 2015.
Online issue publication
April 09, 2020
Article Versions
- Previous version (9 April 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/